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Abstract
Metastasis is a multistep process and the main cause of mortality in lung cancer patients. We previously showed that EGFR
mutations were associated with a copy number gain at a locus encompassing the TWIST1 gene on chromosome 7. TWIST1 is
a highly conserved developmental gene involved in embryogenesis that may be reactivated in cancers promoting both
malignant conversion and cancer progression through an epithelial to mesenchymal transition (EMT). The aim of this study
was to investigate the possible implication of TWIST1 reactivation on the acquisition of a mesenchymal phenotype in EGFR
mutated lung cancer. We studied a series of consecutive lung adenocarcinoma from Caucasian non-smokers for which
surgical frozen samples were available (n=33) and showed that TWIST1 expression was linked to EGFR mutations (P,0.001),
to low CDH1 expression (P,0.05) and low disease free survival (P=0.044). To validate that TWIST1 is a driver of EMT in EGFR
mutated lung cancer, we used five human lung cancer cell lines and demonstrated that EMT and the associated cell mobility
were dependent upon TWIST1 expression in cells with EGFR mutation. Moreover a decrease of EGFR pathway stimulation
through EGF retrieval or an inhibition of TWIST1 expression by small RNA technology reversed the phenomenon.
Collectively, our in vivo and in vitro findings support that TWIST1 collaborates with the EGF pathway in promoting EMT in
EGFR mutated lung adenocarcinoma and that large series of EGFR mutated lung cancer patients are needed to further
define the prognostic role of TWIST1 reactivation in this subgroup.
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Introduction
Lung cancer is the most common cause of cancer death in
western countries. Tumor recurrence and metastasis are frequent
events despite the establishment of multiple lines of therapy and
the introduction of targeted agents [1]. Tyrosine kinase inhibitors
against the epidermal growth factor receptor (EGFR) have been
developed and although the vast majority of patients with lung
cancer failed to respond, a minority showed dramatic tumor
shrinkage. Molecular screenings showed that the presence of an
EGFR activating mutation was highly linked to tumor response
and EGFR mutated tumors were defined as a new entity among
lung cancers [2]. Two alterations account for more than 90% of
the mutants; inframe deletions in exon 19 and the p.L858R
missense mutation that were both shown to activate the EGFR
pathway mainly through PI3K/AKT and STAT3 activation and
to remain at least partially ligand dependent. EGFR mutations are
more common in East Asians, in non-smokers, in women and in
patients with adenocarcinomas (ADC) especially those with
bronchioalveolar (BAC) features. Although it is largely accepted
that patients with EGFR mutated tumors have a better prognosis as
compared others, aggressive tumors with rapid unfavorable
evolution also exist. Prognostic markers have not been specifically
studied in EGFR mutated cancers and could help classify this new
entity [3]. In a previous work, using SNP array, we showed that
tumors with EGFR mutations had a copy number increase of a
region on chromosome 7 (7p21.1-7p15.3) encompassing the
TWIST1 gene, a highly conserved basic helix-loop-helix tran-
scription factor regulator of embryogenesis [4]. This was
confirmed on CGH arrays with 40% of EGFR mutated tumors
showing copy number increase of this region. In order to go
further we focused on TWIST1 and explored whether it could be
the potential target. While TWIST1 is silent in most healthy adult
tissues, it was found overexpressed in various types of carcinomas
[5,6,7,8,9,10,11,12,13]. Described as a pro-metastatic factor,
TWIST1 was found to promote cell motility and invasiveness
through an epithelial-mesenchymal transition (EMT) [14]. In
epithelial cells, EMT induction was related to cooperation
between TWIST1 and mitogenic proteins such as ERBB2 and
RAS. TWIST1 was additionally found to override oncogene-
induced senescence and apoptosis by interfering with both p53
and RB. Therefore both roles on senescence and oncogenic
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29954pathways could drive cell transformation [15,16]. In this work, we
tested the hypothesis that TWIST1 and mutated EGFR could
similarly cooperate in promoting EMT in lung adenocarcinomas.
Our results suggest that TWIST1 is an important driver of EMT
in EGFR mutated cells and could be a potential marker in clinics to
predict outcome in patients with EGFR mutated tumors.
Results
TWIST1 expression is associated with EGFR mutation in
lung cancer
The first objective of this work was to examine whether
TWIST1 reactivation could be associated to EGFR mutation.
Therefore we compared TWIST1 expression, at mRNA and
protein levels, to the EGFR mutational status in a group of tumors
from non-smokers. Among a series of 213 Caucasian patients with
lung ADC, 33 had not smoked or less than 10 pack-year and were
selected for this study. Twenty-two tumors had high quality RNA
available with RQI.7, 30 had Formalin Fixed Paraffin Embed-
ded (FFPE) tissue for Immuno-Histo-Chemistry analyses (IHC)
and 21 were EGFR mutated (Table S1). In this group of non-
smokers high levels of TWIST1 mRNA were found in EGFR
mutated tumors (p,0.001) (Fig. 1A). Moreover TWIST1 mRNA
correlated with TWIST1 positive staining by IHC (p=0.0012).
IHC showed that staining was nuclear and cytoplasmic and
restricted to tumor glands (Fig. 1B). We further explored a
potential interplay between TWIST1 reactivation and EMT in
non-smoker lung cancer. Considering mRNA and protein
information, TWIST1 was positive in only one EGFR wild type
tumor (sample 133). This sample is an adenosquamous carcinoma
it is the only particular non-ADC or BAC in this series.
Unsupervised hierarchical clustering based on CDH1, TWIST1,
CDH2, VIM and JUP mRNA levels showed perfect distinction of
groups according to the EGFR mutational status (Fig. 2A). Patterns
of expression were mostly mesenchymal for the wild type EGFR
tumors suggesting that EMT is not dependent upon TWIST1 in
this group. In the EGFR mutated group, although patterns of
expression were in majority epithelial, low CDH1 correlated with
TWIST1 reactivation at mRNA (p,0.05) (group 1A) and protein
levels (0.017) (Fig. 2B). In order to go further, SNAI1 (SNAIL1) and
ZEB1 were analyzed at RNA level. No ZEB1 reactivation was seen
in either group of tumors but 2 samples, one EGFR mutated
(sample 288) and one EGFR wild type (sample 245) showed SNAI1
reactivation. The EGFR mutated SNAI1 reactivated tumor express
TWIST1, VIM and CDH2 (sample 288) suggesting that TWIST1
and SNAI1 might interact to drive full mesenchymal phenotype
(Table S1).
Furthermore, in patients with EGFR mutated tumors disease
free survival was shorter for patient with TWIST1 reactivated
tumors (IHC positive samples) and reach significance although the
number of patients (n=21) is low and deserve confirmation
(p=0.044).
Collectively, these observations support the assumption that
TWIST1 could promote EMT in EGFR mutated tumors. In order
to validate these observations we examined whether TWIST1 and
EGFR proteins cooperate in promoting EMT and the associated
mobility in human lung cell lines.
Assessment of TWIST1 expression in lung
adenocarcinoma cell lines
We examined whether TWIST1 reactivation was associated
with mutated EGFR in human lung carcinoma cell lines and
related to a mesenchymal phenotype. We first assessed TWIST1
mRNA expression in 5 cell lines including two EGFR wild type:
H358 (KRAS mutated, unknown smoking status) and H1299
(NRAS mutated, smoker) and three EGFR mutated isolated from
non-smokers: H1650, H1975 and HCC827. H1650, H1975 and
HCC827 harbor classic EGFR mutations that can be compared to
the mutations found in our series of patients (an in-frame deletion
in exon 19 for H1650 and HCC827 and the L858R mutation for
H1975). H1299 and H1650 were the only ones with high TWIST1
levels as compared to normal human lung RNA used as calibrator
Figure 1. TWIST1 expression in tumor samples. A. Assessment of TWIST1 expression by quantitative RT-PCR in EGFR mutated (M) and wild type
(WT) tumors assessed by quantitative RT-PCR. B. Representative microphotographs (106) of immunohistochemical expression of TWIST1 in primary
EGFR mutated human lung tumors (sample 230 (1), sample 55 (2), sample 288 (3)) or wild type tumors (sample 149 (4)). Arrows point out cells for
which staining is positive. TWIST1 positive staining is seen for samples 2 and 3 in cytoplasm and nucleus.
doi:10.1371/journal.pone.0029954.g001
TWIST1 and EMT in EGFR Mutated Lung Cancer
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29954(Table 1). Consistently, TWIST1 protein was present in these two
cell-lines. These results show that, as in tumors, TWIST1
reactivation was found in lung cancer cell lines, one is EGFR
mutated and one is NRAS mutated they were established from a
non-smoker and a smoker respectively (Table 1). Light microscopy
examination showed that H1299 cells displayed a mesenchymal
phenotype whereas H1650 cells presented an epithelial morphol-
ogy (Fig. S1). TWIST1 was localized in the cytoplasm in H1650
cells and strictly located in nucleoli in H1299 cells (Fig. 3 A–B).
This observation suggested that signals essential for TWIST1
nuclear localization could be lacking in H1650. Indeed H1299
cells are NRAS mutated (p.Q61K) and have a constitutive
activation of both MAPK and PI3K downstream pathways. As
EGFR activating mutations are known to remain at least partially
ligand dependent in inducing oncogenic signals [2], we next
examined whether EGFR activation by EGF might induce
TWIST1, restore its nuclear localization and contribute to the
induction of EMT. H1650 cells were treated during 4, 12, 24 and
48 hours with EGF at concentrations ranging from 5 to 120 ng/
ml. First modifications in mRNA expression occurred at 24 h,
5 ng/ml (data not showed). All cells were therefore treated at 5
and 25 ng/ml during 24 and 48 hours in triplicate and three
independent experiments. In TWIST1 reactivated EGFR mutant
cells (H1650), EGF was sufficient to induce TWIST1 nuclear
translocation and to promote EMT as indicated by cell
morphologic changes and by the expected shift from epithelial
to mesenchymal markers (Fig. 4 and 5). In cell lines without
TWIST1 reactivation, H358, HCC827 or H1975, EGF did not
modify cell phenotype although two are EGFR mutated. In these
cell lines, at basal state phenotypes can be complex with VIM and
CDH2 expression for H1975 and H358 and a true epithelial
phenotype for HCC827. The analysis of two other EMT
transcription factors, ZEB1 and SNAI1 demonstrated no reactiva-
tion of ZEB1 but overexpression of SNAI1 in H1975 that could
Figure 2. TWIST1 and CDH1 expression are inversely correlated in human lung primary tumors. A. TWIST1, CDH1, JUP, CDH2 and VIM
expressions were assessed by quantitative RT-PCR in human lung primary tumors. Unsupervised hierarchical clustering isolated two groups. EGFR
mutated tumors were classified in group 1 and EGFR wild type tumors in group 2. Group 1A, contains EGFR mutated TWIST1 reactivated tumors (247,
54, 17 and 288) with an intermediate phenotype (high TWIST1, low CDH1, low VIM expression) that could be undergoing an epithelial to
mesenchymal transition. B. Representative microphotographs (206) of immunohistochemical expression of CDH1 (1, 3) and TWIST1 (2, 4) in EGFR
mutated tumors. Positive cells are indicated by arrows. Upper panels: example of tumor (sample 17), expressing a low amount of CDH1 (1) and
TWIST1 (2). Lower panels: example of tumor (sample 18) expressing CDH1 (3) and lacking TWIST1 (4). C. Kaplan-Meier Disease free survival curves
according to TWIST1 reactivation assessed by IHC on lung tumor tissue samples. Disease free survival is shortened in the TWIST1 positive group
(p=0.044).
doi:10.1371/journal.pone.0029954.g002
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these cells at basal state (Table 1; Fig. S1). No up-regulation of
SNAI1 was seen after EFG treatment in this cell line.
To further study the influence of TWIST1 reactivation in a
background of EGFR mutation we focused our work on HCC827
(TWIST-) and H1650 (TWIST+), both are epithelial at basal state,
harbor similar EGFR mutation and were derived from non-
smokers. To explore whether TWIST1 is a prerequisite for EGF
induced EMT in EGFR mutated lung cancer cells, we confirmed
that long time EGF treatment (10 days) did not generate an EMT
in HCC827 TWIST1 negative cells. At the opposite HCC827
switched to a mesenchymal phenotype in response to TGFb. This
TGFb induced EMT was independent of TWIST1 reactivation
strengthening the role of TWIST1 in specifically driving an EGF/
EGFR-induced EMT (Fig. S2).
EMT is known to be a reversible process subjected to
microenvironmental changes. We therefore sought to explore
whether TWIST1-dependent EMT might similarly be reversed
when EGF is released in H1650 cells. Following EGF withdraw,
cells reverted to an epithelial phenotype as indicated by
morphological changes and the expected shift from mesenchymal
to epithelial markers (Fig. S3). Collectively, these results strongly
support the assumption that EGFR activation contributes to
TWIST1 re-localization and thereby promotes EMT.
TWIST1 depletion alleviates EGF induced EMT in EGFR
mutated-TWIST1 expressing cells (H1650)
TWIST1 depletion through RNA interference in H1650 cells
resulted in a slight reduction of mesenchymal markers (CDH2
and VIM) and induction of CDH1 in absence of EGF. This
result was somehow expected as we previously showed that
TWIST1 was localized in the cytoplasm and might not be fully
active at basal state. TWIST1 depletion also resulted in SNAI1
and ZEB1 mRNA decrease (data not showed). Furthermore,
TWIST1 depletion counteract EGF induced EMT in EGFR
mutated-TWIST1 expressing cells (Fig. 6 A–D). Finally
TWIST1 depleted cells maintained an epithelial phenotype
under EGF treatment.
EGFR-TWIST1-induced EMT is associated with a gain in
cellular motility
As EMT is known to drive cell dissemination, we next explored
whether EGF treatment provides cells with motility. To this end,
Figure 3. Basal expression of EMT markers in cell lines. A. Assessment of TWIST1, Vimentin, N-Cadherin, E-Cadherin and Plakoglobin showing
qualitative expression of markers by western blotting. B. Representative photomicrographs of TWIST1 expression in EGFR mutated cell lines (H1650
and HCC827) and in H1299 as assessed by immunofluorescence.
doi:10.1371/journal.pone.0029954.g003
Table 1. Expression of TWIST1, mesenchymal (CDH2, VIM, SNAI1, ZEB1) and epithelial (CDH1, JUP) markers in lung adenocarcinoma
cell lines.
EGFR mutated TWIST1 Mesenchymal markers Epithelial markers
CDH2 VIM SNAI1 ZEB1 CDH1 JUP
H1299 No 13.2160.98 10.9060.09 1.7360.05 0.1260.02 0.4360.13 0.0160.02 0.0160.04
H358 No 0.0860.04 13.0160.12 0.1560.02 2.0460.19 0.0260.01 6.1760.79 1.8060.34
H1650 p.E746-A750del 12.3760.94 0.7660.03 0.0160.36 1.3260.12 0.0160.02 11.7460.20 2.9560.44
H1975 p.L858R/p.T790M 0.0460.12 0.1260.07 1.4560.04 5.3960.22 0.3160.09 2.8560.26 0.9560.05
HCC827 p.E746-A750del 0.1960.10 0.7060.10 0.1060.34 0.2360.14 0.0460.07 6.5161.01 2.3060.32
Assessment of TWIST1, CDH2 (N-Cadherin), VIM (Vimentin), SNAI1 (SNAIL1), ZEB1, CDH1 (E-Cadherin) and JUP (plakoglobin) transcriptional expression by quantitative RT-
PCR. The relative expression levels between samples were calculated using the comparative delta Ct (threshold cycle number). In each run, in addition to study samples,
normal human lung RNA was used as calibrator. Each value represents the mean 6SD of three independent experiments each one run in triplicate.
doi:10.1371/journal.pone.0029954.t001
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type, TWIST1 reactivated) and HCC827 (EGFR mutated,
TWIST1 absent) cell lines were treated with EGF and their
motility was assessed in a scratch assay. As shown in Fig. 7, EGF
treatment resulted in a significant motility gain in H1650 cells
(38% versus 20% after 10 h (p,0.001) and 100% versus 66%
wound closure after 22 h (p,0.001)). These results strengthened
our conclusion that EGFR activation through its ligand is essential
in promoting TWIST1-associated EMT. As expected, EGF did
not impact on HCC827 and H1299 motility (Fig. 7A). Similar
results were obtained when motility was assessed in a migration
assay (Fig. 7B).
These results showed that EGF strictly controlled the EMT-
associated motile phenotype in EGFR mutated and TWIST1
reactivated cells.
Collectively our results suggest the existence of a cooperative
effect between EGF pathway activation and TWIST1 reactivation
in promoting EMT in EGFR mutated lung cancer.
Figure 4. EGF induces EMT only in cells with EGFR mutation and TWIST1 expression. EGFR mutated human lung cancer cell lines (H1975,
H1650, HCC827) were treated with EGF. A. Cell morphology obtained by phase-contrast microscopy. B. TWIST1, CDH2, VIM, CDH1 and JUP expression
as assessed by quantitative RT-PCR. mRNA levels are expressed relative to the untreated control condition. Each column represents the mean 6SD of
3 independent experiments each one done in triplicate.
doi:10.1371/journal.pone.0029954.g004
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EGFR mutations are specific to lung cancer and occur in mainly
non-smokers. This specific subgroup was extensively studied
because of the dramatic sensibility of EGFR mutated cells to
anti-EGFR tyrosine kinase inhibitors (TKI) but the understanding
of tobacco independent lung carcinogenesis is far from being
totally understood. We found that TWIST1, an embryonic
transcription factor actor of the metastatic process [17], was
specifically expressed in tumors with EGFR mutations in a group of
tumors from non-smoker. In one series of Taiwanese patients with
lung cancer TWIST1 expression was shown in 36% of samples but
the relation with EGFR mutational status was not reported [18].
Because TWIST1 and mitogenic proteins (ie ERBB2, RAS) were
found to cooperate in EMT induction [15], we investigated
whether TWIST1 could trigger a mesenchymal phenotype in
EGFR mutated cells.
Consistent with the literature, in our series, most lung tumors
with EGFR mutations were associated with epithelial characteris-
tics [19]. Tumors that were not EGFR mutated demonstrated
higher levels of mesenchymal markers independently of TWIST1
reactivation. Recent findings from Takeyama et al. in lung cancer
cells lines demonstrated that among four master epithelial-to-
mesenchymal transition (EMT)-inducing genes (ZEB1, SIP1,
SNAI1, and SNAI2 (SLUG)) ZEB1 was highly expressed in non-
EGFR mutated mesenchymal cell lines whereas EGFR mutated
cell lines had low ZEB1 expression and an epithelial phenotype
[20]. In our experience non-EGFR mutated human tumors from
Figure 5. EGF induces EMT only in cells with EGFR mutation and TWIST1 expression (protein level). A. Assessment of TWIST1, CDH2, VIM,
CDH1 and JUP expression by western blotting after addition of EGF for a 24 h or 48 h period of time on HCC827 (EGFR mutated, TWIST1 not
expressed) and H1650 (EGFR mutated, TWIST1 expressed). B. Representative photomicrographs of TWIST1, CDH2, VIM, CDH1 and JUP expression
analyzed by immunofluorescence after EGF treatment (25 ng/mL).
doi:10.1371/journal.pone.0029954.g005
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be linked to this phenotype suggesting that other transcription
factors might be implicated. Within the EGFR mutated one, high
TWIST1 expression was related to a significant reduced CDH1
expression, suggesting that among those epithelial tumors, a subset
could have started an EMT program. For these samples, tissue
analysis by the pathologist did not identify any change such as
fibroblastic transformation but morphologic examination of tissues
rarely recognizes mesenchymal features on tissue slides. Indeed,
EMT is a dynamic continuous event that may be difficult to
characterize in tumors because cells might not be at the same state
at the same time leading to tumor heterogeneity [21]. In order to
investigate whether TWIST1 could determine morphological
changes in EGFR mutated tumors we analyzed the effect of
TWIST1 expression in vitro and showed that in EGFR mutated
lung cancer cells, EGF pathway stimulation and TWIST1
cooperated to induce an EMT and the associated cell mobility.
In other tumor models, EGF was shown to trigger an EMT with
up-regulation of either SNAI1 or TWIST1 possibly through
STAT3 activation [8,22]. In our study EGF does not dramatically
enhance TWIST1 expression but is more likely to induce its
nuclear re-localization that associated with the gain of a
mesenchymal phenotype. In this model the loss of CDH1
expression is only an indirect proof but suggests that TWIST1
might directly bind DNA to induce EMT. Post-translational
regulation of TWIST1 might also be mediated through mutated
EGFR activation, indeed, in head and neck cancer, IL6 activation
was recently shown to stabilize TWIST1 through CK2 phosphor-
ylation [23]. The mutated EGFR/TWIST1 interdependence was
validated using RNA silencing. TWIST1 depletion in other
cancers such as prostate and gastric carcinoma also counteract the
EMT program [6]. In our model TWIST1 expression also favored
cell mobility and could therefore enhance the metastatic potential
of tumor cells. Other transcription factors have been implicated in
the acquisition of an EMT such as ZEB1, E47, SNAI1, and SNAI2
[24]. In our experience ZEB1 and SNAI1 were slightly increased in
H1650 cells after EGF treatment and SNAI2 was up-regulated at
protein level suggesting a possible cooperation between transcrip-
tion factors. This was not retrieved for the TWIST1 non-
expressing EGFR mutated cells in which ZEB1 and SNAI1
Figure 6. TWIST1 depletion through RNA interference overrides EMT induction by EGF in H1650 cells. EGFR mutated, TWIST1 expressed
H1650 human lung cells were depleted of TWIST1 through RNA interference. Impact of TWIST1 depletion on epithelial and mesenchymal markers in
absence or in presence of EGF was examined. A. The efficiency of the siRNA was controlled by assessing TWIST1 expression by immunofluorescence.
B. Expression analysis of TWIST1, CDH2, VIM, CDH1 and JUP in absence of EGF treatment by quantitative RT-PCR. Graph shows the relative expression
(siRNA TWIST1/siRNA scramble) for the 5 markers. Each column represents the mean 6SD of 3 independent experiments each one done in triplicate.
C. Impact of TWIST1 depletion on TWIST1, CDH2, CDH1 and JUP protein expression in H1650 cells in absence or in presence of EGF as assessed by
western blotting. D. Impact of TWIST1 depletion on TWIST1, CDH2, VIM, CDH1 and VIM following cell treatment with EGF as assessed by relative
expression (siRNA TWIST1/siRNA scramble). Each column represents the mean 6SD of 3 independent experiments each one done in triplicate.
doi:10.1371/journal.pone.0029954.g006
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EGFR-mutated cells, ZEB1 and SNAI1 up-regulation seems related to
TWIST1 reactivation but other mechanism could drive EMT in
absence of EGF stimulation. Indeed SNAI1 reactivation was found
independently of TWIST1 in H1975 and the mesenchymal aspect of
these cells is independent of EGF stimulation.
Figure 7. EGF-induced EMT associates with a gain in motility. Human lung cell lines harboring different TWIST1 and EGFR status were treated
with EGF and tested for their motility in scratch (panel A) and transwell migration (panel B) assays. A. Phase contrast photographs showing wound
closure for H1650, HCC827 and H1299 cell lines in presence or absence of EGF and corresponding graphs presenting the mean 6SD of wound
closure in 3 independent experiments each one run in triplicate. B. Migration potential assessed by transwell migration. Graphs show the ratio:
number of cells that migrated in the lower chamber in the EGF conditions reported to number of cells that migrated in the lower chamber in absence
of EGF treatment. EGF only enhanced migration in cells with EGFR mutation and TWIST1 reactivation.
doi:10.1371/journal.pone.0029954.g007
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mesenchymal-epithelial transition (MET) when settled in their new
environment [21]. In our model, we confirmed that EGF-driven
EMT was reversible in EGFR mutated TWIST1 expressing lung
cancer cells.
In alternative models TWIST proteins were also shown to
override premature senescence due to mitogenic activities of
oncoproteins [15]. In our experience, TWIST1 depletion using
high siRNA concentration (.100 pmol) led to cell death
suggesting that TWIST1 retrieval allowed cell death to occur in
those cells. TWIST1 effects on cell death could rely on its relation
with the p53 pathway via an inhibition of ARF mRNA expression.
We had previously found an association between ARF-CDKN2A
homozygous deletions and EGFR mutations [4]. In this study, 5
tumors had an ARF-CDKN2A homozygous deletion and none
reactivated TWIST1. Also work is needed to validate this finding
we can suspect that in tumors without ARF-CDKN2A deletion
TWIST1 reactivation could override oncogene premature senes-
cence by interacting with CDKN2A (Table S1). Finally EMT has
previously been implicated in resistance to chemotherapy [25] and
because TWIST1 may be linked to cell death inhibition its role on
sensitivity to TKI should be further investigated.
Collectively our results report for the first time that EGF
induced EMT in EGFR mutated lung tumors is driven by
TWIST1 reactivation. Indeed the transition from epithelial to
mesenchymal phenotype as well as the associated increased
mobility is dependent upon both TWIST1 and EGF activation
in vitro. This in vitro model is coherent with our in vivo observations.
Moreover TWIST1 in tumors could also counteract oncogene-
induced senescence through ARF-CDKN2A. Although further work
is warranted to confirm this finding our results show that even in
localized lung tumors TWIST1 may be reactivated and is
associated with EMT. This work supports the idea that in EGFR
mutated lung tumors TWIST1 reactivation could promotes
progression through EMT induction and needs to be evaluated
in prospective series as a new prognosis marker.
Materials and Methods
Ethic Statements
Tumors were retrospectively selected in the European Georges
Pompidou hospital tumor bank in accordance to French laws from
patients that had specified orally or by written consent to the
surgeon that they were not opposed to the use of their surgical
tumor samples for research purpose. Patients had finished their
treatment at collection time. Tissue bank and annotations were
anonymized and no connection between clinics and research was
possible.
Our study was subjected to the ethic committee ‘‘Comite ´d e
Protection des Personnes, Ile de France II’’ (Committee for the
Protection of People) linked to the Paris Descartes University that
qualified the 213 clinical specimens for research use (NuCPP Ile de
France II 2008-136). Moreover, the collection was declared at and
approved by the Research and Education Ministry, DC-2008-401,
NuID-RCB: 2008-A00880-55.
Case selection
Primary lung cancer were prospectively collected and stored
frozen at time of surgery from 2004 to 2006 in the Georges
Pompidou European hospital in Paris. Among the consecutive
adenocarcinoma cases (n=213), 33 were non-smokers. These
tumors had previously been characterized for mutation testing at
EGFR, TP53, KRAS, BRAF, PI3KCA, STK11, ERBB2 and AKT1
and for CDKN2A homozygous deletion table S1 [4].
Briefly, patients had surgery as first line treatment for NSCLC
and adjuvant treatment if necessary following standardized
guidelines. Survival data were retrospectively collected and time
to first relapse post surgery was considered for relapse free survival
analysis.
RNA extraction and Real-Time Reverse Transcriptase-PCR
Total RNAs from cell lines and frozen tumor samples, 100 slices
(7 mm) cut on a cryostat, were extracted using RNeasyH Mini kit
(Qiagen). Two HES slides were done at the beginning and the end
of tissue slices confirming the existence of more than 70% of
tumors cells. RNA quality was estimated by the RQI (RNA quality
indicator) using high-resolution electrophoresis system (Experi-
on
TM, Biorad, Paris).
RNAs (2 mg) were reversed-transcribed using the Reverse
Transcription Kit (Applied Biosystem). mRNA levels of TWIST1,
CDH1, CDH2, JUP, SNAI1, ZEB1 and VIM were quantified by
SYBR green real-time polymerase chain reaction (PCR) on an
ABI Prism 7900 sequence detector system (Applied Biosystems,
Foster City, CA). Real-time PCR was performed in triplicate
reactions with 20 ng of cDNA using SYBR Green PCR Master
Mix (Applied Biosystems). In each run, normal human lung RNA
(Clontech) was used as calibrator. We used POLR2A (Polymerase
RNA II polypeptide A), RPL13A (Ribosomal Protein L13A), YAP1
(Yes-Associated Protein 1) and 18S RNAs as the endogenous genes
controls. The relative expression levels between samples were
calculated as described by Livak et al. [26]. All experiments were
run in triplicates and in 3 independent PCR experiments. Primer
sequences are detailed in Table S2.
Cell culture experiments
Lung adenocarcinoma cell lines (H358, H1299, H1650, H1975
and HCC827) were obtained from the American Type Culture
Collection (ATCC) and grown at 37uC, 5% CO2 in RPMI 1640
supplemented with 10% fetal bovine serum (PAA). Before EGF
treatments, cells were serum starved for 24 h then EGF
(Invitrogen) was supplemented to 2% foetal bovin serum culture
media at two concentrations (5 ng/mL and 25 ng/mL) and
treatment times (24 h and 48 h).
TWIST1 small interfering RNA experiment
Cells were seeded in six-well culture plates in culture medium
supplemented with 10% foetal bovine serum. The next day,
transfection was done with either TWIST1 or scrambled siRNAs
at concentration ranging from 20 to 100 rmoles (siRNA TWIST1,
Santa Cruz). Co-treatment with EGF was done as follow: after 6 h
of contact with siRNA transfection reagents, EGF was added to
the transfection media (5 or 25 ng/mL) for 24 h and treatment
was expanded 24 h more with EGF containing medium alone.
Cellular morphology was observed and mRNAs were collected.
Protein isolation and western blots
Proteins wereextracted inRIPA buffer.Total proteinextracts(30
or 40 mg/lane) were subjected to analysis protein expression was
examined using TWIST1 (Abcam), VIM (Santa Cruz) and JUP
(SantaCruz) monoclonal antibodies and Actin(Sigma), CDH1 (Cell
Signaling) and CDH2 (Santa Cruz) polyclonal antibodies. Blots
were revealed with horseradish peroxydase-conjugated secondary
antibodies (Dako) and ECL Detection Kit (Amersham).
Immunofluorescence and deconvolution microscopy
Cells were seeded onto glass slides 24 h prior to treatments with
EGF. Cells were then treated with EGF, fixed in cold methanol,
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incubated with similar primary antibodies as for western blots.
Secondary antibodies marked with FITC (Jackson ImmunoR-
esearch) were added for 1 h at room temperature. Cells were
mounted in medium with DAPI to label nuclei. After mounting,
cells were examined with 406 oil immersion objective (Nikon
Eclipse TE-2000E) and AutoQuant X software (MediaCyberrntic)
was used to deconvolve z series images.
Migration assays
Two-dimensional migration assay was performed using a
scratch wound model. Migration status was analyzed by residual
wound measure at 0 h, 2 h, 6 h, 10 h and 22 h using an inverted
phase contrast microscope equipped with a digital camera (Nikon
Digital shot DS-L1).
Three-dimensional cell migration assay was performed using
the ThinCert
TM cell culture insert 12-well plates composed of
polycarbonate membrane containing 8 mm pores (Greiner bio-
one). Cells mobility is estimated by the number of cells contained
in the lower chamber quantified by numeration in Malassez
counting chamber.
Immunohistochemistry
After HES review, 33 tumors were available for immunohisto-
chemistry (IHC). 4 mm-thick sections were deparaffinized using
xylene for CDH1 (Cell Signaling) and toluene for TWIST1
(Abcam). CDH1 was performed with an automatic immunostainer
Bond III (Leica, Wetzlar, Germany). TWIST1 staining was
performed manually. Antigen retrieval was achieved by micro-
wave in citrate buffer pH 6.0. Then, we used the kit UltraVision
LP detection (Thermo Scientific). The immunostained sections
were examined microscopically by two independent pathologists
not aware of the patients’ clinical data.
Statistical analyses
All the data are representative of at least three experiments.
Values are expressed as mean6sd. Qualitative variables were
tested using Mann-Whitney test and Fisher’s exact test. Statistical
analysis was carried out using GraphPad Prism 4.0 software
(GraphPad Prism Software, Inc., San Diego, CA), STATA 11.0
College Station, TX and R software Bioconductor package. The
clustering was built using heatmap from made4 package. Survival
functions were estimated using the Kaplan-Meier method.
Difference was tested by log-rank test.
Supporting Information
Figure S1 Basal morphology of lung adenocarcinoma
cell lines. H1650, H1975 and HCC827 are EGFR mutated,
H358 and H1299 are EGFR wild type. Representative photomi-
crograph of cells was obtained by phase-contrast microscopy.
(TIF)
Figure S2 Impact of EGF removal on EMT markers in
H1650. Image shows the modification of cell morphology up on
EGF removal. Graphs show the evolution of EMT marker
expression up on EGF removal in H1650 cells by quantitative RT-
PCR. mRNA levels are expressed relative to the untreated control
condition.
(TIF)
Figure S3 Impact of TGFb treatment on EMT markers
in HCC827. HCC827 cells were treated with TGFb or EGF
during 24, 48 h and 10 days at 25 ng/mL. A. After treatment,
representative photomicrograph of cells was obtained by phase-
contrast microscopy. B. Expression of TWIST1, CDH2, VIM,
CDH1 and JUP was measured by quantitative RT-PCR, after
TGFb or EGF treatments. Each column represents the mean
6SD of 9 wells and three independent experiments.
(TIF)
Figure S4 ZEB1, SNAI1 and SNAI2 in EGFR mutated cell
lines. Summary of mRNA regulation after EGFR treatment in
three EGFR mutated cell lines. (2): down-regulation, (+) up-
regulation, (/) no difference according to non tumor reference.
Detailed information for H1650 (EGFR mutated/TWIST1
reactivated) is shown (A) up-regulation of ZEB1 at RNA level at
4 and 24 h treatment, (B) transitory up-regulation of SNAI1 at 4 h
treatment (C) up regulation of SNAI2 at protein level WB and IF
experiments.
(TIF)
Table S1 Summary of tumor samples characteristics.
Description of the tumor samples series in terms of clinico-
pathological features, gene mutation (EGFR, TP53,KRAS, BRAF,
ERBB2, PIK3CA, STK11 and AKT1) as well as CDKN2A gene copy
number.
(PDF)
Table S2 Primer sequence for quantitative RT-PCR
analyses.
(PDF)
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